



**HAL**  
open science

## **Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality**

Anne Hiance-Delahaye, Florence Muller de Schongor, Laurent Lechowski, Laurent Teillet, Jean-Jacques Arvieu, Jm Robine, Joël Ankri, Marie Herr

### ► **To cite this version:**

Anne Hiance-Delahaye, Florence Muller de Schongor, Laurent Lechowski, Laurent Teillet, Jean-Jacques Arvieu, et al.. Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality. *International Psychogeriatrics*, 2017, 17, pp.1 - 12. <10.1017/S1041610217002290>. <inserm-01764264>

**HAL Id: inserm-01764264**

**<https://inserm.hal.science/inserm-01764264v1>**

Submitted on 11 Apr 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

## **Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality**

Anne Hiance-Delahaye, Florence Muller de Schongor, Laurent Lechowski, Laurent Teillet, Jean-Jacques Arvieu, Jean-Marie Robine, Joël Ankri, Marie Herr, Florence Muller De Schongor, Marie Robine, et al.

### **► To cite this version:**

Anne Hiance-Delahaye, Florence Muller de Schongor, Laurent Lechowski, Laurent Teillet, Jean-Jacques Arvieu, et al.. Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality. *International Psychogeriatrics*, Cambridge University Press (CUP), 2017, pp.1 - 12. <10.1017/S1041610217002290>. <inserm-01764264>

**HAL Id: inserm-01764264**

**<http://www.hal.inserm.fr/inserm-01764264>**

Submitted on 11 Apr 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality**

Anne Hiance-Delahaye<sup>(1,2,3,4)</sup>, Florence Muller de Schongor<sup>(1)</sup>, Laurent Lechowski<sup>(1,4)</sup>, Laurent Teillet<sup>(1,4)</sup>, Jean-Jacques Arvieu<sup>(5)</sup>, Jean-Marie Robine<sup>(6,7)</sup>, Joël Ankri<sup>(2,3,5)</sup>, Marie Herr<sup>(2,3,5)</sup>

(1) Service de Gériatrie, Hôpital Sainte Perine, HUPIFO, AP-HP, Paris, France

(2) INSERM, U1168, VIMA: Aging and Chronic diseases. Epidemiological and Public Health approaches, Villejuif, F-94807, France

(3) Univ Versailles St-Quentin-en-Yvelines, UMR-S 1168, F-78180, Montigny le Bretonneux, France

(4) Univ Versailles St-Quentin-en-Yvelines, F-78180, Montigny le Bretonneux, France

(5) Département Hospitalier d'Epidémiologie et de Santé Publique, Hôpital Sainte Péline, APHP, Paris, France

(6) AG2R La Mondiale, Direction des Etudes, Prévoyance Individuelle et IARD, Paris, France

(7) INSERM U988 et U1198, EPHE, Paris & Montpellier, France

Correspondence : Anne Hiance-Delahaye, Service de Gériatrie, 11 rue Chardon Lagache, 75016, Paris, France,

Tel : +33 (0) 144 96 31 31, e-mail: [anne.delahaye@aphp.spr.fr](mailto:anne.delahaye@aphp.spr.fr)

## Abstract

**Background:** The increasing use of antidepressants (ADs) has raised concerns about their inappropriate use in old people. **Objective:** To examine the prevalence of potentially inappropriate prescriptions (PIPs) of ADs, their associated factors, and their impact on mortality in a sample of old people in France. **Methods:** The analysis used data from the SIPAF study, a cross-sectional study consisting of 2350 people aged  $\geq 70$  years. Trained nurses interviewed participants at home between 2008 and 2010. Information was collected concerning socio-demographic and health characteristics, including medication use. The study population consisted of the 318 AD users from the SIPAF study (13.5%). PIP of ADs was defined according to national and international criteria. Factors associated with PIP of ADs were assessed using a multivariate logistic regression model. The influence of PIP of ADs on mortality was assessed using a Cox model (median follow up 2.8 years). **Results:** Among the SIPAF study, 71% of AD users were female and the mean age was  $84 \pm 7$  years. Selective serotonin reuptake inhibitors (SSRIs) were the most prescribed ADs (19.8%). We found PIP of ADs in 36.8% of the study population, mainly the co-prescription of diuretics with SSRIs (17.6%) and the prescription of tricyclics (12.9%). PIP of ADs was associated with polypharmacy (aOR<sub>5-9 drugs</sub> 2.61, 95% CI 1.11-6.16 and aOR <sub>$\geq 10$  drugs</sub> 2.69, 95% CI 1.06-6.87) and comorbidity (aOR<sub>3-4 chronic diseases</sub> 2.59, 95%CI 1.04-6.44 and aOR <sub>$\geq 5$  chronic diseases</sub> 2.33, 95%CI 0.94-5.79), and increased the risk of mortality during follow-up (aHR 2.30, 95%CI 1.28-4.12). **Conclusion:** This study shows that more than one third of AD prescriptions may be inappropriate in old people. PIP of ADs was related to polypharmacy and comorbidity and increased mortality among AD users.

**Keywords:** Antidepressants, Adverse Events, Community care, Epidemiology.

## Introduction

Depression is one of the most frequent mental disorders in older adults and is a serious public health problem. The prevalence of depression after 75 years of age is estimated to be 7.2% (95% CI 4.4-10.6%) for major depression and 17.1% (95% CI 9.7-26.1%) for depressive disorders (Luppa et al., 2012). Late-life depression is associated with disability and risk of death, independently of lifestyle and socioeconomic factors (Diniz et al., 2014).

Antidepressants (ADs) may effectively treat this invalidating illness in older people, with a range of therapeutic options including second generation ADs such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (Girardi et al., 2009; Kok and Reynolds, 2017). Their use has substantially increased during the last decades, especially SSRIs (Noordam et al., 2015). An American study reported that percentage of community-dwelling people aged  $\geq 65$  years receiving ADs increased from 9.8% in 1996 (n = 2,349) to 13.7% in 2005 (n = 3,474) (Olfson and Marcus, 2009). A population-based study conducted in Australia estimated that the use of ADs increased by 41% between 2002 and 2007 and that people aged 90-94 years were the largest consumers (Hollingworth et al., 2011). In Europe, the use of ADs doubled between 1993 and 2002 (Knapp, Martin et al., 2006), especially in nursing homes (Ruths et al., 2013).

The increasing use of AD can be explained by new indications (*e.g.* for SSRI: generalized anxiety disorder, panic, obsessive compulsive disorder, and post-traumatic stress disorder) (Raymond et al., 2007), increasing duration of treatment (Moore et al., 2009) and increased prescription of ADs by non-psychiatrist physicians (Mojtabai and Olfson, 2011).

Extensive use of ADs in old people has raised concerns about misuse and a subsequent increase in the risk of drug interactions and adverse events, such as osteoporosis and osteopenia, bleeding, hypertension or orthostatic hypotension, arrhythmia, and falls (Diniz and Reynolds, 2014). Older adults are likely to have altered drug metabolism and clearance, co-existing physical disorders, sensory deficits or other disabilities that call for caution when prescribing ADs (Kennedy and Marcus, 2005). An American study (Wang et al., 2005) revealed that among 12,130 new AD users aged  $\geq 65$  years, 43% received suboptimal treatment, because of the use of anticholinergic drugs, excessively high or low daily dosages, short duration therapy or inadequate follow-up. A cross-sectional study in France showed that ADs represented 28.4% of the potentially inappropriate use of psychotropic drugs according to the 2003 Beers list (Prudent et al., 2008).

Potentially inappropriate prescribing (PIP) in old people has become a major healthcare concern because of its association with adverse drug events, hospitalizations, and use of healthcare resources (Mort and Aparasu, 2000). Specific studies concerning PIP of ADs are currently limited to nursing-home residents (Bourgeois et al., 2012; Hanlon et al., 2011).

The main objective of this study was to describe the prevalence of and factors associated with PIP of ADs in a sample of people aged  $\geq 70$  years in France. The secondary objective was to assess the impact of PIP of ADs on mortality.

## **Methods**

### **Study population**

This is a secondary analysis of the data from the SIPAF study, a cross-sectional study carried out to characterize health and functional independence among people  $\geq 70$  years. The study population was composed of the 318 AD users included in the SIPAF study (13.5%). Participants in the SIPAF study were selected at random among recipients of a supplementary pension fund (AG2R La Mondiale, Paris, France), with over-representation of the oldest-old. Recruitment took place from 2008 to 2010 in all regions of mainland France. The participation rate was 18.9% (details about participation are given elsewhere) (Herr et al., 2014). Information was collected at home by trained nurses. In 16.6% of cases, a close relative attended the interview to confirm or complete the answers of the participants. The information concerning deaths among the study population was provided by AG2R La Mondiale, with follow-up ending June 5, 2012 (median follow-up 2.8 years). Participants gave their written informed consent and the research protocol was approved by an independent ethics committee (permission n\_060316).

### **Data collection and geriatric assessment**

The following information about socio-demographic characteristics and general health was collected: age, gender, marital status, level of education, higher level of occupation between husband and wife, drinking and smoking habits, self-rating of health relative to people of the same age, and hospitalizations in the prior six months. Participants reporting chronic diseases were asked to identify their problem(s) among the list of 14 chronic diseases used to monitor population health by the European Commission (Robine et al., 2003), including chronic anxiety/depression. The number of years with depressive and/or anxiety symptoms was assessed by

asking people who reported chronic anxiety and/or depression: “How long have you been suffering from this condition?” (variable expressed in tertiles). In addition to self-reported chronic diseases, we identified cardiovascular fragility by the prescription of at least one of the following drugs: antiarrhythmic or digitalic or coronary vasodilator drugs.

Geriatric problems were specifically investigated. Nutritional impairment was defined by a body mass index of 21 kg/m<sup>2</sup> or lower and/or unintentional weight loss of 10% of body weight during the prior six months. Questions about physical and sensory limitations dealt with the ability to see newspaper print clearly and to see the face of someone 4 m away, and to distinctly hear what is said in a conversation with another person. Impaired mobility was defined as difficulty walking more than 500 meters and/or difficulty walking up and down one floor of stairs. Social isolation was defined by lack of support with practical features (when bedridden or when needing to be accompanied to a medical appointment or when needing help to prepare meals) and/or emotional features (when needing to talk or when needing advice or affection). Assessment of activity restrictions examined six activities of daily living according to Katz et al (Katz et al., 1963), *i.e.* “bathing, dressing, toileting, transferring, continence, and feeding”, as well as instrumental activities of daily living (IADL) (Lawton and Brody, 1969) such as food preparation, the ability to use a phone, housekeeping, shopping and the ability to manage one’s finances. Homebound status was defined as the incapacity to leave home without help. Depression was suspected in participants with a score >5 on the 15-item Geriatric Depression Scale (Yesavage et al., 1982). Cognitive impairment was defined as a score ≤ 26 on the Mini-Mental State Examination (Folstein and McHugh, 1975) and/or prescription of an anti-Alzheimer drug (Folstein et al., 1975).

### **Medications**

Medications taken by the participants were assessed by asking the participants about their treatments and information was completed by reviewing the prescriptions participants had at home. The question was formulated as follows: “What medications are you currently taking? Could you show me your last prescriptions please?” Participants were invited to indicate whether they did not take some of the drugs prescribed to reduce the gap between drugs prescribed and those actually taken. Drugs were coded using the Anatomical Therapeutic Chemical Classification (ATC) System. Polypharmacy was defined as five drugs or more and excessive polypharmacy as 10 drugs or more. ADs were identified by the codes N06AA (tricyclic antidepressants - TCAs), N06AB (SSRIs), N06AG (monoamine oxidase inhibitors - MAOIs), and N06AX (SNRIs and other ADs, namely mianserin, tianeptine, and mirtazapine).

PIP of ADs was defined according to the 2015 Beers list (American Geriatrics Society 2015 Beers Criteria Update Expert Panel, 2015), Laroche list (Laroche et al., 2007) and STOPP criteria v2 (O'Mahony et al., 2015). We also took into account French guidelines (ANSM, *Agence Nationale de Sécurité du Médicament*) published in 2006, Canadian guidelines from "Canadian Network for Mood and Anxiety Treatments" (CANMAT), and English guidelines from the "National Institute for Health and Clinical Excellence" (NICE), both published in 2009. The entire set of PIP of AD retrieved from these sources is shown in Table 1.

### **Statistical analysis**

Descriptive statistics present the characteristics of the study population and AD treatments. Categorical variables are described with percentages and continuous variables with the mean +/- standard deviation (SD). Bivariate and multivariate analyses were performed to identify the factors related to PIP of ADs among AD users. Variables associated with a  $p < 0.20$  in bivariate analysis as well as age and gender were introduced into the multivariate analysis. The multivariate analysis used a logistic regression model. The final model was obtained using backward stepwise analysis ( $p$  value for removal  $> 0.10$ ). The results are presented with odds ratios (OR) and 95% confidence intervals (CI). The effect of PIP of ADs on mortality was assessed using a Cox proportional hazard model. The Schoenfeld test showed that there was no evidence against the proportional Hazard assumption ( $p = 0.142$ ). Results are presented using Hazard Ratios (HR) and 95% CI. Statistical analyses were performed using STATA<sup>®</sup> software, version 13.0 (Stata Corp., College Station, TX).

## **Results**

### **Study population**

Among the 318 AD users included in this study, 71% were female and mean age was  $84 \pm 7$  years. We observed excessive polypharmacy (10 drugs or more) in 29.3% of the study population ( $n = 93$ ). Socio-demographic and health characteristics of the study population are described in Table 2.

### **AD use**

AD use is described in Table 3. SSRIs were the most prescribed ADs, especially paroxetine (19.8%), followed by escitalopram (9.4%) and citalopram (9.4%). Venlafaxine was the most prescribed SNRIs (10.7%). TCAs were

prescribed in 12.9% of the study population, amitriptyline in most cases. “Other antidepressants”, such as mianserin were prescribed in 25.5% of the study population.

At least one PIP of ADs was identified for 117 AD users (36.8%). The prevalence of the different PIP of ADs is shown in Table 1. Concomitant prescription of SSRIs and diuretics was the most frequent PIP of ADs (17.6%), followed by the prescription of TCAs (12.9%), and concomitant prescription of SSRIs and non-steroidal anti-inflammatory drugs (NSAIDs) or anti-vitamin K drugs, in 6.0% and 3.8% of the study population respectively.

### **Factors associated with PIP of AD**

Bivariate analysis showed that PIP of ADs was associated with low self-perceived health, hospitalization in the prior six months, polypharmacy, number of chronic diseases, and cognitive impairment. Conversely, PIP of ADs was not associated with the level of education, tobacco smoking, alcohol consumption, nutritional impairment, impaired mobility, the use of other psychotropic drugs, level of dependency or sensory impairment (Table 2). Polypharmacy and comorbidity were the only factors that remained significantly associated with PIP of ADs in multivariate analysis. Polypharmacy was associated with PIP of ADs with adjusted  $OR_{5-9 \text{ drugs}} 2.61$  (95% CI 1.11-6.16 and  $OR_{\geq 10 \text{ drugs}} 2.69$  (95% CI 1.06-6.87), independently of the number of chronic diseases and cognitive impairment (Table 4).

Subgroup analysis among people who reported the duration of their depressive and/or anxiety symptoms (n=160) showed that the longer the duration of symptoms, the higher the risk of PIP of ADs, with an adjusted OR 2.82 (95% CI 1.42-6.99) for people suffering from depressive and/or anxiety symptoms for  $\geq 28$  years relative to those who reported symptoms for  $\leq 7$  years.

### **PIP of AD and mortality**

During follow-up, 29.5% of people with at least one PIP of ADs died, versus 18.4% of those a PIP of ADs (p=0.025). PIP of AD was associated with increased mortality (HR 2.30, 95% CI 1.28-4.12) after adjustment for age, gender, polypharmacy, number of chronic diseases, nutritional impairment, cognitive impairment, dependency, hospitalization in the prior six months, and GDS score (Table 5, survival curves available in Appendix 1).

## **Discussion**

### **Main findings**

Based on international and national guidelines, we found that 36.8% of people  $\geq 70$  years received *a priori* suboptimal AD treatment in a French observational study. Drug-drug interactions between SSRIs and diuretics and prescription of TCAs were the most frequent PIPs. In multivariate analysis, the only factors associated with PIP of ADs were polypharmacy and comorbidity. Survival analysis (median follow-up of 2.8 years) suggests that PIP of ADs is associated with increased mortality among AD users.

### **Drug-drug interactions with SSRIs**

The most frequently reported PIP of ADs was the association of SSRIs and diuretics (17.6%). This association increases the risk of hyponatremia caused by SSRIs, especially when thiazide diuretics are involved (Mannesse et al., 2013). Hyponatremia is associated with cognitive impairment (Gunathilake et al., 2013) and increases the risk of osteoporosis and bone fractures (Usala et al., 2015). The biological mechanisms of this interaction may involve syndrome of inappropriate secretion of antidiuretic hormone (SIADH) or nephrogenic syndrome of inappropriate antidiuresis (NSIAD) by increasing sensitivity of the kidneys to ADH via aquaporine-2 expression (Mannesse et al., 2013).

Here, concomitant use of SSRIs with NSAIDs or antivitamin K drugs represented 6.0% and 3.8% of the PIP of ADs respectively. There is evidence that SSRIs increase the risk of upper gastrointestinal bleeding, particularly when they are associated with NSAIDs (de Abajo and García-Rodríguez, 2008). The role of serotonin in the ability of platelets to aggregate may explain this effect. Indeed, the use of SSRIs has been shown to increase the risk of major haemorrhage events in patients taking warfarin (Quinn et al., 2014). Antivitamin K drugs are biotransformed by the P450 system and SSRIs potentially inhibit various isoenzymes (Sansone and Sansone, 2009). Thus, it is recommended that people treated with warfarin and starting treatment with an SSRI have their International Normalized Ratio (INR) regularly monitored to detect interactions (Afssaps, 2006; Lam et al., 2015; Pilling et al., 2009).

### **TCAs**

In our study, TCAs represented the second most frequent PIP of ADs, with a prevalence of 12.9% among AD users. This is similar to the results of a cross-sectional study among 1306 inpatients aged  $\geq 75$  years in France (Prudent et al., 2008). Among the 263 inpatients treated by ADs, 29 (11%) received TCAs. Amitriptyline has been identified as the most inappropriately prescribed AD among people  $\geq 65$  years in community settings (Opondo et al., 2012) and nursing homes (Bourgeois et al., 2012). Reasons for the use of TCAs, and amitriptyline in particular, may involve the management of treatment-resistant depression, indications for

conditions other than depression itself (such as neuropathic pain) and off-label use (*e.g.* for pain, insomnia, and migraine) (Wong et al., 2017). TCAs may have notable side effects resulting from their strong anticholinergic activity (*i.e.* dry mouth, blurred vision, urinary retention, and constipation) and cardiovascular adverse effects (*i.e.* orthostatic hypotension and arrhythmia) (Gareri et al., 2000; Mintzer and Burns, 2000). Thus, TCA are not recommended as a first-line treatment (Afssaps, 2006; O'Mahony et al., 2015). An Australian study (Caughey et al., 2010) showed that approximately one third of patients receiving TCAs had arrhythmia, ischemic heart disease or chronic heart failure. The prevalence of concomitant cardiovascular fragility and TCAs prescription in our study was very low (3%) but this may be an under-estimation, as information concerning cardiovascular diseases was not extensively detailed in the SIPAF study.

### **Factors associated with PIP of ADs**

The main factors associated with PIP of ADs were polypharmacy and comorbidity. This finding was expected because polypharmacy, related to comorbidity, is a well-known determinant of PIP in general (Projovic et al., 2016) and of PIP of psychotropic drugs in particular (Carey et al., 2008). Although expected, this result is worrisome because of the very large proportion of our sample of AD users exposed to polypharmacy (86.1% received at least 5 medications, versus 67.4% in the entire population of the SIPAF study). This study highlights the need for review of drug therapy among elderly AD users, by considering the appropriateness of each drug, both individually and in the context of the other drugs being prescribed (Wise, 2013).

In a subgroup analysis, the duration of depression and/or anxiety symptoms was also associated with PIP of ADs. This association has not been reported elsewhere and suggests that prolonged AD treatment increases the risk of PIP, probably because the prescription is not reassessed. Furthermore, long-term prescription of AD treatment may be contraindicated because of the risks of osteoporosis and fractures (Diniz and Reynolds, 2014).

### **Association between PIP of ADs and mortality**

This study suggests that PIP of ADs is significantly associated with mortality. Previous findings regarding the association between inappropriate prescribing, not restricted to ADs, and mortality are contradictory. Both positive (Sköldunger et al., 2015) and negative associations (Onder et al., 2005; Page and Ruscin, 2006) have been reported. Methodological issues may explain these discrepancies, such as the lack of adjustment for important confounders (*e.g.* number of chronic diseases, polypharmacy), short follow-up or small and selected samples. Concerning inappropriate prescribing of ADs or other psychotropic drugs, previous observational studies suggested an association with mortality, although they encountered difficulty distinguishing the effect of

AD drugs from those of depression itself. The results of our study were adjusted for the intensity of depressive symptoms according to the GDS 15, but we cannot exclude residual confounding.

### **Strength and limitations of the study**

The main strength of the SIPAF study was the collection of diverse health data among a sample of elderly recruited from throughout mainland France, including a large proportion of oldest-old. Concerning medication data, the examination of participants' prescriptions at home minimized recall bias.

We performed a comprehensive assessment of PIP of ADs, using validated and updated explicit criteria (2015 Beers, Laroche and STOPP version 2), as well as recommendations. Explicit tools have many advantages, as they are highly reproducible and applicable to large scale studies of patients at a limited cost, and have demonstrated their utility in assessing the quality of drug therapy at the population level (Morin et al., 2015). However, they artificially simplify complex situations by excluding the individuals' health history and preferences (Spinewine et al., 2007).

The SIPAF study was not specifically designed to answer the questions of the present study. Thus, we lack useful information regarding AD prescriptions, notably the indication, dosage, and duration of treatment. Consequently, we could not analyze underuse or overuse, nor misuse of ADs taking into account the symptoms that led to the prescription of AD, which may be depressive and/or anxiety disorders but also neuropathic pain (TCAs). Furthermore, the association between the duration of depressive and/or anxiety symptoms and PIP of ADs should be interpreted with caution because data may suffer from recall bias.

Concerning the association between PIP of ADs and mortality, we cannot exclude residual confounding by morbidity because we used a standard list of 14 chronic diseases that does not take into account their severity. Finally, mortality is not the ultimate arbiter of risk and benefit for medications but we were unable to measure the impact of PIP of ADs on adverse drug events or quality of life, nor could we assess the potential clinical benefits of AD use.

### **Conclusion**

PIP of ADs was observed among more than one third of our study population aged  $\geq 70$  years and mainly involved interactions between SSRIs and diuretics and the prescription of TCAs. PIP of ADs was associated with polypharmacy and comorbidity and increased the risk of mortality among AD users. These findings highlight the

need for greater caution in the use of ADs in the elderly. Areas for improvement may include specific training of General Practitioners, facilitating access to geriatric or psychiatric consultations, and reinforcement of the role of the community pharmacist in medication review. Both observational and interventional studies are needed to assess the long-term consequences of PIP of ADs and evaluate the effects of de-prescription of ADs in old people.

**Conflicts of interest:** None to declare. Anne Hiance-Delahaye carried out the statistical analysis and wrote the paper. Marie Herr supervised the statistical analysis and helped to write the paper. Joël Ankri, Jean-Marie Robine and Jean-Jacques Arvieu designed the SIPAF study, supervised data collection, and critically reviewed the paper. Florence Muller, Laurent Lechowski and Laurent Teillet critically reviewed the paper.

**Acknowledgments:** Thanks to Alex Edelman & Associates for English editing.

## References

- Afssaps, 2006. Bon usage des médicaments antidépresseurs dans le traitement des troubles dépressifs et des troubles anxieux de l'adulte. Afssaps.
- American Geriatrics Society 2015 Beers Criteria Update Expert Panel, 2015. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J. Am. Geriatr. Soc.* 63, 2227–2246. doi:10.1111/jgs.13702
- Bourgeois, J., Elseviers, M.M., Van Bortel, L., Petrovic, M., Vander Stichele, R.H., 2012. The use of antidepressants in Belgian nursing homes: focus on indications and dosages in the PHEBE study. *Drugs Aging* 29, 759–769. doi:10.1007/s40266-012-0003-6
- Carey, I.M., De Wilde, S., Harris, T., Victor, C., Richards, N., Hilton, S.R., Cook, D.G., 2008. What factors predict potentially inappropriate primary care prescribing in older people? Analysis of UK primary care patient record database. *Drugs Aging* 25, 693–706.
- Caughey, G.E., Roughead, E.E., Shakib, S., McDermott, R.A., Vitry, A.I., Gilbert, A.L., 2010. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. *Age Ageing* 39, 488–494. doi:10.1093/ageing/afq055
- de Abajo, F.J., García-Rodríguez, L.A., 2008. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. *Arch. Gen. Psychiatry* 65, 795–803. doi:10.1001/archpsyc.65.7.795
- Diniz, B.S., Reynolds, C.F., 2014. Major Depressive Disorder in Older Adults: Benefits and Hazards of Prolonged Treatment. *Drugs Aging*. doi:10.1007/s40266-014-0196-y
- Diniz, B.S., Reynolds, C.F., Butters, M.A., Dew, M.A., Firmo, J.O.A., Lima-Costa, M.F., Castro-Costa, E., 2014. The effect of gender, age, and symptom severity in late-life depression on the risk of all-cause mortality: the Bambuí Cohort Study of Aging. *Depress. Anxiety* 31, 787–795. doi:10.1002/da.22226

- Folstein, M.F., Folstein, S.E., McHugh, P.R., 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* 12, 189–198.
- Gareri, P., Falconi, U., De Fazio, P., De Sarro, G., 2000. Conventional and new antidepressant drugs in the elderly. *Prog. Neurobiol.* 61, 353–396.
- Girardi, P., Pompili, M., Innamorati, M., Mancini, M., Serafini, G., Mazzarini, L., Del Casale, A., Tatarelli, R., Baldessarini, R.J., 2009. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. *Hum. Psychopharmacol.* 24, 177–190. doi:10.1002/hup.1005
- Gunathilake, R., Oldmeadow, C., McEvoy, M., Kelly, B., Inder, K., Schofield, P., Attia, J., 2013. Mild hyponatremia is associated with impaired cognition and falls in community-dwelling older persons. *J. Am. Geriatr. Soc.* 61, 1838–1839. doi:10.1111/jgs.12468
- Hanlon, J.T., Wang, X., Castle, N.G., Stone, R.A., Handler, S.M., Semla, T.P., Pugh, M.J., Berlowitz, D.R., Dysken, M.W., 2011. Potential Underuse, Overuse and Inappropriate Use of Antidepressants in Older Veteran Nursing Home Patients. *J. Am. Geriatr. Soc.* 59, 1412–1420. doi:10.1111/j.1532-5415.2011.03522.x
- Herr, M., Arvieu, J.-J., Aegerter, P., Robine, J.-M., Ankri, J., 2014. Unmet health care needs of older people: prevalence and predictors in a French cross-sectional survey. *Eur. J. Public Health* 24, 808–813. doi:10.1093/eurpub/ckt179
- Hollingworth, S.A., Lie, D.C., Siskind, D.J., Byrne, G.J., Hall, W.D., Whiteford, H.A., 2011. Psychiatric drug prescribing in elderly Australians: time for action. *Aust. N. Z. J. Psychiatry* 45, 705–708. doi:10.3109/00048674.2011.594947
- Katz, S., Ford, A.B., Moskowitz, R.W., Jackson, B.A., Jaffe, M.W., 1963. Studies of Illness in the Aged: The Index of ADL: A Standardized Measure of Biological and Psychosocial Function. *JAMA* 185, 914–919. doi:10.1001/jama.1963.03060120024016
- Kennedy, G.J., Marcus, P., 2005. Use of antidepressants in older patients with co-morbid medical conditions: guidance from studies of depression in somatic illness. *Drugs Aging* 22, 273–287.

- Knapp, Martin, McDaid, David, Mossialos, Elias, Thornicroft, Graham, 2006. WHO/Europe | Publications - Mental health policy and practice across Europe. The future direction of mental health care.
- Kok, R.M., Reynolds, C.F., 2017. Management of Depression in Older Adults: A Review. *JAMA* 317, 2114–2122. doi:10.1001/jama.2017.5706
- Lam, R.W., Parikh, S.V., Michalak, E.E., Dewa, C.S., Kennedy, S.H., 2015. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. *Ann. Clin. Psychiatry Off. J. Am. Acad. Clin. Psychiatr.* 27, 142–149.
- Laroche, M.-L., Charmes, J.-P., Merle, L., 2007. Potentially inappropriate medications in the elderly: a French consensus panel list. *Eur. J. Clin. Pharmacol.* 63, 725–731. doi:10.1007/s00228-007-0324-2
- Lawton, M.P., Brody, E.M., 1969. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. *The Gerontologist* 9, 179–186. doi:10.1093/geront/9.3\_Part\_1.179
- Luppa, M., Sikorski, C., Luck, T., Ehreke, L., Konnopka, A., Wiese, B., Weyerer, S., König, H.-H., Riedel-Heller, S.G., 2012. Age- and gender-specific prevalence of depression in latest-life--systematic review and meta-analysis. *J. Affect. Disord.* 136, 212–221. doi:10.1016/j.jad.2010.11.033
- Mannesse, C.K., Jansen, P.A.F., Van Marum, R.J., Sival, R.C., Kok, R.M., Haffmans, P.M.J., Egberts, T.C.G., 2013. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. *Maturitas* 76, 357–363. doi:10.1016/j.maturitas.2013.08.010
- Mintzer, J., Burns, A., 2000. Anticholinergic side-effects of drugs in elderly people. *J. R. Soc. Med.* 93, 457–462. doi:10.1177/014107680009300903
- Mojtabai, R., Olfson, M., 2011. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. *Health Aff. Proj. Hope* 30, 1434–1442. doi:10.1377/hlthaff.2010.1024

- Moore, M., Yuen, H.M., Dunn, N., Mullee, M.A., Maskell, J., Kendrick, T., 2009. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. *BMJ* 339, b3999.
- Morin, L., Fastbom, J., Laroche, M.-L., Johnell, K., 2015. Potentially inappropriate drug use in older people: a nationwide comparison of different explicit criteria for population-based estimates. *Br. J. Clin. Pharmacol.* 80, 315–324. doi:10.1111/bcp.12615
- Mort, J.R., Aparasu, R.R., 2000. Prescribing potentially inappropriate psychotropic medications to the ambulatory elderly. *Arch. Intern. Med.* 160, 2825–2831.
- Noordam, R., Aarts, N., Verhamme, K.M., Sturkenboom, M.C.M., Stricker, B.H., Visser, L.E., 2015. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. *Eur. J. Clin. Pharmacol.* 71, 369–375. doi:10.1007/s00228-014-1803-x
- Olfson, M., Marcus, S.C., 2009. National patterns in antidepressant medication treatment. *Arch. Gen. Psychiatry* 66, 848–856. doi:10.1001/archgenpsychiatry.2009.81
- O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M.N., Ryan, C., Gallagher, P., 2015. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing* 44, 213–218. doi:10.1093/ageing/afu145
- Onder, G., Landi, F., Liperoti, R., Fialova, D., Gambassi, G., Bernabei, R., 2005. Impact of inappropriate drug use among hospitalized older adults. *Eur. J. Clin. Pharmacol.* 61, 453–459. doi:10.1007/s00228-005-0928-3
- Opondo, D., Eslami, S., Visscher, S., de Rooij, S.E., Verheij, R., Korevaar, J.C., Abu-Hanna, A., 2012. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. *PloS One* 7, e43617. doi:10.1371/journal.pone.0043617
- Page, R.L., Ruscin, J.M., 2006. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. *Am. J. Geriatr. Pharmacother.* 4, 297–305. doi:10.1016/j.amjopharm.2006.12.008

- Pilling, S., Anderson, I., Goldberg, D., Meader, N., Taylor, C., Two Guideline Development Groups, 2009. Depression in adults, including those with a chronic physical health problem: summary of NICE guidance. *BMJ* 339, b4108.
- Projovic, I., Vukadinovic, D., Milovanovic, O., Jurisevic, M., Pavlovic, R., Jacovic, S., Jankovic, S., Stefanovic, S., 2016. Risk factors for potentially inappropriate prescribing to older patients in primary care. *Eur. J. Clin. Pharmacol.* 72, 93–107. doi:10.1007/s00228-015-1957-1
- Prudent, M., Dramé, M., Jolly, D., Trenque, T., Parjoie, R., Mahmoudi, R., Lang, P.-O., Somme, D., Boyer, F., Lanièce, I., Gauvain, J.-B., Blanchard, F., Novella, J.-L., 2008. Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort. *Drugs Aging* 25, 933–946.
- Quinn, G.R., Singer, D.E., Chang, Y., Go, A.S., Borowsky, L.H., Udaltsova, N., Fang, M.C., 2014. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. *Am. J. Cardiol.* 114, 583–586. doi:10.1016/j.amjcard.2014.05.037
- Raymond, C.B., Morgan, S.G., Caetano, P.A., 2007. Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. *Psychiatr. Serv. Wash. DC* 58, 79–84. doi:10.1176/appi.ps.58.1.79-a
- Robine, J.-M., Jagger, C., Euro-REVES Group, 2003. Creating a coherent set of indicators to monitor health across Europe: the Euro-REVES 2 project. *Eur. J. Public Health* 13, 6–14.
- Ruths, S., Sørensen, P.H., Kirkevold, Ø., Husebø, B.S., Krüger, K., Halvorsen, K.H., Selbaek, G., 2013. Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts. *Int. J. Geriatr. Psychiatry* 28, 868–876. doi:10.1002/gps.3902
- Sansone, R.A., Sansone, L.A., 2009. Warfarin and Antidepressants: Happiness without Hemorrhaging. *Psychiatry Edgmont Pa Townsh.* 6, 24–29.
- Sköldunger, A., Fastbom, J., Wimo, A., Fratiglioni, L., Johnell, K., 2015. Impact of Inappropriate Drug Use on Hospitalizations, Mortality, and Costs in Older Persons and Persons with

- Dementia: Findings from the SNAC Study. *Drugs Aging* 32, 671–678. doi:10.1007/s40266-015-0287-4
- Spinewine, A., Schmader, K.E., Barber, N., Hughes, C., Lapane, K.L., Swine, C., Hanlon, J.T., 2007. Appropriate prescribing in elderly people: how well can it be measured and optimised? *The Lancet* 370, 173–184. doi:10.1016/S0140-6736(07)61091-5
- Usala, R.L., Fernandez, S.J., Mete, M., Cowen, L., Shara, N.M., Barsony, J., Verbalis, J.G., 2015. Hyponatremia Is Associated With Increased Osteoporosis and Bone Fractures in a Large US Health System Population. *J. Clin. Endocrinol. Metab.* 100, 3021–3031. doi:10.1210/jc.2015-1261
- Volkert, J., Schulz, H., Härter, M., Wlodarczyk, O., Andreas, S., 2013. The prevalence of mental disorders in older people in Western countries - a meta-analysis. *Ageing Res. Rev.* 12, 339–353. doi:10.1016/j.arr.2012.09.004
- Wang, P.S., Schneeweiss, S., Brookhart, M.A., Glynn, R.J., Mogun, H., Patrick, A.R., Avorn, J., 2005. Suboptimal antidepressant use in the elderly. *J. Clin. Psychopharmacol.* 25, 118–126.
- Wise, J., 2013. Polypharmacy: a necessary evil. *BMJ* 347, f7033. doi:10.1136/bmj.f7033
- Wong, J., Motulsky, A., Abrahamowicz, M., Egualé, T., Buckeridge, D.L., Tamblyn, R., 2017. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ* 356, j603.
- Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., Leirer, V.O., 1982. Development and validation of a geriatric depression screening scale: a preliminary report. *J. Psychiatr. Res.* 17, 37–49.

**Table 1. Prevalence of PIP of ADs according to national and international criteria (Beers, Laroche, STOPP/START and prescription guidelines)**

Risk medications used	Medication name	WHO ATC classification	Potential(s) risk(s)	Reference(s)	n (%) (***)
TCA alone	Amitriptyline Clomipramine Imipramine Trimipramine Doxepine Amoxapine Maprotiline Dosulepine	N06AA09 N06AA04 N06AA02 N06AA06 N06AA12 N06AA17 N06AA21 N06AA16	Highly anticholinergic, sedative and causes orthostatic hypotension	Laroche et al. (2009) Beers et al. (2015)	41 (12.9)
TCA associated with calcium inhibitors or opioids		C08 and N02A	May exacerbate constipation	O'Mahony et al. (2015)	12 (3.7)
TCA associated with cardio-vascular fragility (**)			Increases the risk of cardiac events (cardiac conduction slowing, arrhythmia, orthostatic hypotension)	Beers et al. (2015) O'Mahony et al. (2015)	9 (2.8)
TCA associated with cognitive impairment (*)			Risk of worsening cognitive impairment	O'Mahony et al. (2015)	6 (1.9)
TCA associated with anticholinergic drugs	Phenothiazine neuroleptic Doxylamine Aceprometazine Alimemazine Promethazine Mequitazine Carbinoxamine Hydroxyzine Brompheniramine Chlorphenamine Cyproheptadine Buclizine Oxybutynine Tolterodine Solifenacine	N05AA and N05AC R06AA09 N05CV01 R06AD01 N06AD02 R06AD07 R06AA09 N05BB01 R06AD01 R06AB04 R06AX02 R06AE51 G04BD04 G04BD07 G04BD08	Increases anticholinergic effects	Lang et al. (2015) Laroche et al. (2009)	0
SSRI associated with diuretics		N06AB and C03	Increases risk of hyponatremia	Beers et al. (2015) ANSM (2006)	56 (17.6)

SSRI associated with NSAID or antivitamin K drug	N06AB and B01AA or N02BA	Increases risk of gastro- intestinal bleeding	ANSM (2006) NICE (2009) CANMAT (2009)	31 (9.8)
Concomitant use of two ADs		No improved efficacy but increase of adverse effects	Laroche et al. (2009) O'Mahony et al. (2015)	11 (3.5)

Abbreviations; ADs = antidepressants; ANSM = Agence Nationale de Sécurité des Médicaments; CANMAT = Canadian Network for Mood and Anxiety Treatments; NICE = National Institute for Health and Clinical Excellence; NSAIDs = non-steroidal anti-inflammatory drugs; PIP of ADs = Potentially Inappropriate Prescription of Antidepressants; SNRIs = serotonin-norepinephrine reuptake inhibitors; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic antidepressants.

(\* ) Cognitive impairment defined as a score lower than 26 to the Mini-Mental State Examination and/or prescription of an anti-Alzheimer drug.

(\*\* ) Cardiovascular fragility defined as prescription of at least one of the following drugs: antiarrhythmic or digitalic or coronary vasodilator drugs.

(\*\*\* ) The total number of PIP is greater than 117 because some participants had multiple PIPs.

**Table 2. Characteristics of the study sample**

Variables	Total, N=318 n (%)	Group with PIP of ADs, N=117 n (%)	Group without PIP of ADs, N=201 n (%)	p
<b>Socio-demographic characteristics, lifestyle, and general health</b>				
Age group				
- 70-89 years	92 (28.9)	32 (27.4)	60 (29.9)	0.444
- 80-89 years	157 (49.4)	63 (53.8)	94 (46.8)	
- ≥ 90 years	69 (21.7)	22 (18.8)	47 (23.4)	
Gender				
- Male	92 (28.9)	30 (25.6)	62 (30.8)	0.324
- Female	226 (71.1)	87 (74.4)	139 (69.2)	
Level of education				
- Low (less than 7 years)	101 (32.1)	33 (28.5)	68 (34.2)	0.576
- Intermediate (between 7 and 10 years)	157 (49.8)	61 (52.6)	96 (48.2)	
- High (more than 10 years)	57 (18.1)	22 (19.0)	35 (17.6)	
Socio professional category (couple)				
- Low	51 (16.0)	18 (15.4)	33 (16.4)	0.966
- Intermediate	158 (49.7)	59 (50.4)	99 (49.3)	
- High	109 (34.3)	40 (34.2)	69 (34.3)	
Married or living in couple	110 (34.7)	42 (36.2)	68 (33.8)	0.875
Tobacco smoking	120 (37.7)	40 (34.2)	80 (39.8)	0.319
Alcohol consumption (3 or more glasses per day)	13 (7.5)	4 (6.7)	9 (8.0)	0.758
Self-rating of health relative to -people of the same age				
- Better	86 (28.7)	24 (21.8)	62 (32.6)	0.134*
- Similar	173 (57.7)	70 (63.6)	103 (54.2)	
- Worse	41 (13.7)	16 (14.5)	25 (13.2)	
Hospitalization in the prior 6 months	65 (20.7)	29 (25.4)	36 (18)	0.118*
<b>Geriatric assessment</b>				
Nutritional impairment	55 (17.5)	18 (15.5)	37 (18.6)	0.488
Cognitive impairment (score on MMSE)				
- > 26	242 (80.4)	88 (77.9)	154 (82.0)	0.183*
- 20-26	33 (11.0)	17 (15.0)	16 (8.5)	
- < 20	26 (8.6)	8 (7.1)	18 (9.6)	
Number of chronic diseases				
- 0-2	40 (12.7)	9 (7.6)	31 (15.7)	0.126*
- 3-4	130 (41.4)	50 (43.1)	80 (40.4)	
- ≥5	144 (45.9)	57 (49.1)	87 (43.9)	
Impaired mobility <sup>(a)</sup>	130 (79.8)	51 (81.0)	79 (79)	0.763
Polypharmacy				
- 1-4 drugs	44 (13.8)	8 (6.8)	36 (17.9)	0.019*
- 5-9 drugs	181 (56.9)	70 (59.8)	111 (55.2)	
- ≥10 drugs	93 (29.2)	39 (33.3)	54 (26.8)	
Use of other psychotropic drugs				
- Anxiolytic and/or hypnotic drugs	159 (50.0)	59 (50.4)	100 (49.8)	0.907
- Antipsychotic drugs	14 (4.4)	7 (6.0)	7 (3.5)	0.295
Level of dependency				
- Independent	136 (42.8)	48 (41.0)	88 (43.8)	0.830
- Need of help for ≥ 1 ADL	85 (26.7)	31 (26.5)	54 (26.9)	
- Need of help for ≥ 1 IADL	97 (30.6)	38 (32.5)	59 (29.4)	
Urinary incontinence				
- Never	165 (52.2)	60 (52.2)	105 (52.2)	0.294
- Occasional	84 (26.6)	26 (22.6)	58 (28.9)	
- Regular	67 (21.2)	29 (25.2)	38 (18.9)	
Depressive syndrome (score on 15-item GDS)				
- < 5	199 (63.0)	72 (61.5)	127 (63.8)	0.826
- 5-10	86 (27.2)	32 (27.4)	54 (27.1)	
- > 10	31 (9.8)	13 (11.1)	18 (9.0)	
Number of years with anxiety and/or depression				
- 0-7	63 (37.7)	10 (16.7)	45 (42.1)	0.048*
- 8-27	61 (36.5)	12 (20.0)	41 (38.3)	
- ≥28	43 (25.8)	38 (63.3)	21 (19.6)	
Social isolation <sup>(b)</sup>	123 (38.7)	49 (33.3)	74 (36.8)	0.371
Visual impairment	52 (16.8)	20 (17.4)	32 (16.4)	0.823
Hearing impairment	128 (40.3)	42 (35.9)	86 (42.8)	0.227

Abbreviations: ADL = Activities of daily living; GDS = Geriatric Depression Scale; IADL = Instrumental Activities of Daily Living; MMSE = Mini Mental State Evaluation; PIP of ADs = Potentially Inappropriate Prescription of Antidepressants.

(a) Impaired mobility was defined by difficulty walking more than 500 meters and/or difficulty walking up and down one floor of stairs.

(b) Social isolation was defined by lack of support with practical features (when bedridden or when needing to be accompanied to a medical appointment or when needing help to prepare meals) and/or emotional features (when needing to talk or when needing advice or affection)

\* p<0.20

**Table 3. Use of ADs in the study population (n=318)**

<b>Classes of ADs</b>	<b>n (%)</b>
<b>TCA</b> s	<b>41 (12.9)</b>
- Amitriptyline	21 (6.6)
- Clomipramine	12 (3.8)
- Dosulépine	4 (1.3)
- Maprotiline	2 (0.6)
- Trimipramine	1 (0.3)
- Amoxapine	1 (0.3)
<b>SSRI</b> s	<b>159 (50)</b>
- Paroxetine	63 (19.8)
- Escitalopram	30 (9.4)
- Citalopram	30 (9.4)
- Fluoxetine	18 (5.7)
- Sertraline	17 (5.3)
- Fluvoxamine	1 (0.3)
<b>SNRI</b> s	<b>46 (14.4)</b>
- Venlafaxine	34 (10.7)
- Duloxetine	10 (3.1)
- Milnacipran	2 (0.6)
<b>MAOI</b> s	
- Moclobemide	2 (0.6)
<b>Others</b>	<b>81 (25.5)</b>
- Mianserin	39 (12.3)
- Tianeptine	29 (9.1)
- Mirtazapine	13 (4.1)

Abbreviations: ADs: antidepressants; MAOIs = monoamine oxidase inhibitors; SNRIs = serotonin-norepinephrine reuptake inhibitors; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic antidepressants.

**Table 4. Factors associated with PIP of ADs: results of the unadjusted and adjusted analysis**

Variables	Crude OR (95% CI)	p	Adjusted OR (95% CI)	p
Age group				
- 70-79 years	1.00		1.00	
- 80-89 years	1.26 (0.74-2.14)	0.402	1.10 (0.62-1.94)	0.761
- 90 years and older	0.88 (0.45-1.70)	0.700	0.82 (0.39-1.73)	0.605
Gender				
- Female	1.00		1.00	
- Male	0.77 (0.46-1.29)	0.324	0.69 (0.40-1.20)	0.194
Cognitive impairment (score on MMSE)				
- > 26	1.00		1.00	
- 20-26	1.86 (0.89-3.86)	0.096	2.17 (0.99-4.75)	0.053
- < 20	0.78 (0.35-1.86)	0.573	1.11 (0.43-2.89)	0.830
Number of chronic diseases				
- 0-2	1.00		1.00	
- 3-4	2.15 (0.95-4.90)	0.067	2.59 (1.04-6.44)	0.041*
- ≥5	2.26 (1.00-5.09)	0.050	2.33 (0.94-5.79)	0.069
Polypharmacy				
- 1-4 drugs	1.00		1.00	
- 5-9 drugs	2.84 (1.25-6.46)	0.013*	2.61 (1.11-6.16)	0.029*
- ≥10 drugs	3.25 (1.36-7.76)	0.008*	2.69 (1.06-6.87)	0.038*

Abbreviations: OR = Odds Ratio; MMSE = Mini Mental State Evaluation; PIP of ADs = Potentially Inappropriate Prescription of Antidepressants

\* p<0.05

**Table 5. Influence of PIP of ADs on survival (median follow-up of 2.8 years): results of the unadjusted and adjusted survival analysis**

Variables	Crude HR (95% CI)	p	Adjusted HR (95% CI)	p
<b>Age group</b>				
- 70-79 years	1.00		1.00	
- 80-89 years	3.61 (1.61-8.10)	0.002*	3.87 (1.47-10.23)	0.006*
- 90 years and older	6.09 (2.62-14.16)	<0.001*	3.37 (1.18-9.69)	0.024*
<b>Gender</b>				
- Female	1.00		1.00	
- Male	3.22 (2.00-5.18)	<0.001*	4.81 (2.72-8.49)	<0.001*
<b>Hospitalization in the prior 6 months</b>				
- No	1.00		1.00	
- Yes	2.01 (1.21-3.35)	0.007*	1.95 (1.05-3.63)	0.035*
<b>Cognitive impairment (score on MMSE)</b>				
- > 26	1.00		1.00	
- 20-26	2.63 (1.33-5.17)	0.005*	2.29 (1.07-4.89)	0.032
- < 20	3.37 (1.72-6.63)	<0.001*	3.40 (1.43-8.06)	0.006*
<b>Level of dependency</b>				
- Independent	1.00		1.00	
- Need of help for $\geq$ 1 ADL	2.23 (1.10-4.53)	0.027*	3.20 (1.37-7.46)	0.007*
- Need of help for $\geq$ 1 IADL	4.73 (2.56-8.75)	<0.001*	3.42 (1.55-7.54)	0.002*
<b>Number of chronic diseases</b>				
- 0-2	1.00		1.00	
- 3-4	1.24 (0.62-2.47)	0.543	1.16 (0.52-2.59)	0.713
- $\geq$ 5	0.94 (0.50-1.76)	0.845	0.59 (0.27-1.25)	0.169
<b>Polypharmacy</b>				
- 0-4 drugs	1.00		1.00	
- 5-9 drugs	1.16 (0.48-2.80)	0.735	1.64 (0.57-4.68)	0.357
- $\geq$ 10 drugs	2.59 (1.07-6.28)	0.034*	4.04 (1.29-12.63)	0.016*
<b>Nutritional impairment</b>				
- No	1.00		1.00	
- Yes	1.96 (1.15-3.33)	0.013*	2.71 (1.45-5.10)	0.002*
<b>PIP of ADs</b>				
- No	1.00		1.00	
- Yes	1.64 (1.02-2.63)	0.040*	2.30 (1.28-4.12)	0.005*
<b>Depressive syndrome (score on the 15-item GDS)</b>				
- < 5	1.00		1.00	
- 5- 10	1.67 (0.99-2.79)	0.053	0.68 (0.36-1.27)	0.227
- > 10	1.26 (0.56-2.83)	0.576	0.41 (0.13-1.33)	0.136

Abbreviations: ADL = Activities of daily living; GDS = Geriatric Depression Scale; HR = Hazard Ratio; IADL = Instrumental Activities of Daily Living; MMSE = Mini Mental State Evaluation; PIP of ADs = Potentially Inappropriate Prescription of Antidepressants.

\* p<0.05